Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.32 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17140968 | 0.89 | ME2 (0.33) | ENPP2 | |
| SCHEMBL17140992 | 0.89 | ENPP2 (0.38) | ENPP2 | |
| SCHEMBL17140628 | 0.88 | ALDH1A1 (0.35) | ENPP2OPRM1OPRL1 | |
| SCHEMBL17140987 | 0.86 | ALDH1A1 (0.41) | — | |
| SCHEMBL18940792 | 0.86 | CYP2C9 (0.36) | ITGB3ITGA2B | |
| SCHEMBL17141087 | 0.85 | ITGAL (0.36) | ENPP2 | |
| SCHEMBL17140871 | 0.84 | MAPT (0.37) | — | |
| SCHEMBL17140941 | 0.84 | ENPP2 (0.40) | ENPP2 | |
| SCHEMBL18940800 | 0.84 | MAPT (0.38) | GPR119ENPP2CHRNA7 | |
| SCHEMBL17141174 | 0.82 | EPHX2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180282332-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2018-10-04 | — | — | US | disclosed |
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170166568-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| EP-3125895-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015154023-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX DISCOVERY, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166568-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | ITGB3 480/4885ITGA2B 179/4885GPR119 1754/4885 |
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, CXCR3, SLC10A1 | ITGB3 502/4885ITGA2B 151/4885GPR119 1770/4885 |
| US-20180282332-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, CXCR3, SLC10A1 | ITGB3 502/4885ITGA2B 151/4885GPR119 1770/4885 |
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | ITGB3 480/4885ITGA2B 179/4885GPR119 1754/4885 |
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, SLC10A1, CXCR3 | ITGB3 480/4885ITGA2B 179/4885GPR119 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.